MXC products now for sale via leading UK e-tailer, Cult Beauty
Published 14-FEB-2018 10:53 A.M.
|
2 minute read
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Specialist medical cannabis company, MGC Pharmaceuticals (ASX:MXC) today announced that its range of MGC Derma and Derma Plus cosmetics products are now available on leading global online beauty store, Cult Beauty (Cultbeauty.com). The launch follows an earlier sales and distribution agreement between MXC’s European subsidiary, MGC Derma, and Cult Beauty.
Cult Beauty will offer 15 of MXC’s cannabidiol cosmetic products and its Derma plus skincare range for sale to its customers in the UK and around the world. Sales will be driven by a 6-month exclusive marketing campaign led by Cult Beauty and additional public relations and promotional activities, with feature articles already secured in leading fashion industry publications.
CultBeauty.com are expert curators and trend dictators. They distil the global beauty industry down to its brightest and best; from the latest scientific discoveries, to hundred-year-old remedies that have never been bettered.
Yet it remains a speculative stock and investors and investors should take a cautious approach to any investment decision made with regard to this stock.
The agreement with the world-renowned beauty products e-tailer provides MXC’s Derma division with a new platform to market its growing range of CBD-based skin care products to a new and more diverse global cosmetics market.
Roby Zomer, Co-founder and CEO, MGC Pharmaceuticals commented: “We’re excited our MGC Derma and Derma Plus products have been officially launched on the Cult Beauty online beauty site and are available to be purchased by its global customer base, where legally permitted.
“Cult Beauty is known for its careful selection, curation and promotion of the products available on its site. The launch places our products alongside some of the beauty industry’s leading cult products, providing exposure of our brand and product range to a whole new market, which is now hearing about the benefits of our CBD-based skincare range.”
General Information Only
S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
